- ClearPoint Neuro ( NASDAQ: CLPT ) on Tuesday said it had received a U.S. FDA medical device clearance for its Maestro Brain Model.
- The brain model was given a so-called 510(k) clearance.
- CLPT said the Maestro model was intended to label, visualize and shape the brain segments and structures from a set of MRI images.
- The software was developed to automate these processes.
- CLPT separately announced Q2 results , with GAAP EPS coming in-line with estimates and revenue beating expectations.
- ClearPoint ( CLPT ) stock +6.8% to $15.50 after hours.
For further details see:
FDA approves ClearPoint Neuro's brain imaging and modelling medical device